Shire-Movetis NV, a prominent biopharmaceutical company headquartered in Belgium, focuses on developing innovative treatments for gastrointestinal disorders. Founded in 2008, the company has made significant strides in the industry, particularly with its flagship product, the novel therapy for irritable bowel syndrome. With a strong presence in Europe and expanding operations in other regions, Shire-Movetis is recognised for its commitment to research and development, ensuring that its offerings address unmet medical needs. The company’s unique approach combines scientific expertise with patient-centric solutions, positioning it as a leader in the gastrointestinal sector. Notable achievements include successful partnerships and a growing portfolio of specialised therapies, solidifying its reputation in the biopharmaceutical landscape.
We don't have data for Shire-Movetis NV, but we can show you information about their parent organization instead.
View parent company